San Diego-based mostly Viking Therapeutics marked itself as a significant competitor from the weight loss drug industry in February following revealing promising details from the mid-phase trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when presented to be a weekly injection As well as in Ma